Identification of an H-Ras nanocluster disrupting peptide 

Candy Laura Steffen et al.

Commun Biol. 2024 Jul 9;7(1):837. doi: 10.1038/s42003-024-06523-9.

Published on July 9, 2024

 

ABSTRACT

Hyperactive Ras signalling is found in most cancers. Ras proteins are only active in membrane nanoclusters, which are therefore potential drug targets. We previously showed that the nanocluster scaffold galectin-1 (Gal1) enhances H-Ras nanoclustering via direct interaction with the Ras binding domain (RBD) of Raf. Here, we establish that the B-Raf preference of Gal1 emerges from the divergence of the Raf RBDs at their proposed Gal1-binding interface. We then identify the L5UR peptide, which disrupts this interaction by binding with low micromolar affinity to the B- and C-Raf-RBDs. Its 23-mer core fragment is sufficient to interfere with H-Ras nanoclustering, modulate Ras-signalling and moderately reduce cell viability. These latter two phenotypic effects may also emerge from the ability of L5UR to broadly engage with several RBD- and RA-domain containing Ras interactors. The L5UR-peptide core fragment is a starting point for the development of more specific reagents against Ras-nanoclustering and -interactors.

PMID:38982284 | PMC:PMC11233548 | DOI:10.1038/s42003-024-06523-9

 Read More

Back to Publications
Recent Publication
Prince Dadson et al.Int J Obes (Lond). 2026 Oct 16. doi: 10.1038/s41366-026-02243-8. Online ahead of print.
Recent Publication
Jiaqi Yan et al.Biomaterials. 2026 Sep 30;338(Pt A):124669. doi: 10.1016/j.biomaterials.2026.124669. Online ahead of print.
Recent Publication
Prabesh Baniya et al.EXCLI J. 2026 Aug 20;25:1383-1387. doi: 10.17179/excli2026-9646. eCollection 2026.
Recent Publication
Hampus Grönvall et al.Brain Behav Immun Health. 2026 Sep 17;57:101365. doi: 10.1016/j.bbih.2026.101365. eCollection 2026 Nov.
Recent Publication
Haifeng Xu et al.Mult Scler Relat Disord. 2026 Sep 24;115:107944. doi: 10.1016/j.msard.2026.107944. Online ahead of print.